When should an adult with LDL‑C ≥190 mg/dL, premature atherosclerotic cardiovascular disease, or a first‑degree relative with early coronary disease or familial hypercholesterolemia undergo a comprehensive genetic lipid panel, and which genes should be sequenced?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Genetic Lipid Panel for Suspected Familial Hypercholesterolemia

Adults with LDL-C ≥190 mg/dL should undergo genetic testing for familial hypercholesterolemia (FH) when they have at least one first-degree relative with similar hypercholesterolemia or premature coronary artery disease, or when LDL-C reaches ≥250 mg/dL even without family history. 1

When to Order Genetic Testing

Strong Indications (Should Offer Testing)

Primary criteria requiring genetic testing:

  • LDL-C ≥190 mg/dL (measured on ≥2 occasions after lifestyle modification) PLUS at least one of:

    • First-degree relative with LDL-C ≥190 mg/dL
    • First-degree relative with premature CAD (men ≤55 years, women ≤65 years)
    • Family history unavailable (e.g., adoption) 1

  • LDL-C ≥250 mg/dL (measured on ≥2 occasions) even without positive family history 1

  • LDL-C >190 mg/dL (≥2 measurements) in the context of the 2023 International Atherosclerosis Society criteria 2

Secondary Indications (May Consider Testing)

  • LDL-C ≥160 mg/dL with family history of both hypercholesterolemia AND premature CAD, plus either:

    • Personal history of premature CAD, OR
    • Family history of premature CAD 1

  • Premature ASCVD with no pretreatment LDL-C available but family history of both hypercholesterolemia and premature CAD 1

Critical caveat: Always exclude secondary causes before testing—hypothyroidism, diabetes, renal disease, nephrotic syndrome, liver disease, and medications that elevate LDL-C 1

Which Genes to Sequence

The standard FH genetic panel should include three primary genes:

  1. LDLR (LDL receptor gene) - most common cause
  2. APOB (apolipoprotein B-100 gene)
  3. PCSK9 (proprotein convertase subtilisin/kexin type 9 gene)

1

Additional genes may be warranted based on specific phenotypic features, though these three capture the vast majority of monogenic FH cases. The 2023 guideline emphasizes that comprehensive genetic testing increases diagnostic accuracy 2.

Clinical Context and Rationale

The evidence strongly supports genetic testing in this population because:

  • Diagnostic yield is low but clinically critical: Only 1.7% of those with LDL-C ≥190 mg/dL carry an FH mutation, BUT mutation carriers have a 22-fold increased CAD risk compared to 6-fold risk in non-carriers with similar LDL-C levels 3. This dramatic difference reflects lifelong cumulative LDL exposure.

  • Enables cascade screening: Once a pathogenic variant is identified in the index case, all at-risk family members should undergo cascade genetic testing 2, 1. This is the most cost-effective method for identifying new FH cases.

  • Improves outcomes: Recent data from the 2026 ACCURATE study demonstrates that opportunistic genetic testing in young adults with premature ACS increased definite FH diagnosis from 0% to 10%, improved LDL-C goal attainment (73% vs 53% achieving <1.8 mmol/L), and intensified lipid-lowering therapy 4.

Important Pitfalls to Avoid

Do not use adult phenotypic criteria (like Dutch Lipid Clinic Network criteria) in children or during cascade testing 2. These scoring systems were designed for index case identification, not family screening.

Recognize that negative genetic testing does not exclude FH: Approximately 70% of clinically diagnosed FH cases do not have an identifiable mutation with current panels 1. These patients may have polygenic hypercholesterolemia or mutations in undiscovered genes. They still require aggressive lipid management.

Ensure genetic counseling: Pre-test and post-test genetic counseling should be provided by healthcare professionals with expertise in FH and genetics 2. This addresses concerns about genetic privacy, life insurance implications, and interpretation of variants of uncertain significance.

Practical Implementation

Measure LDL-C on at least two separate occasions, ideally fasting, before making testing decisions 2. If pretreatment values are unavailable, total cholesterol thresholds of ≥320 mg/dL (corresponding to LDL-C ≥250 mg/dL) or ≥260 mg/dL (corresponding to LDL-C ≥190 mg/dL) can substitute 1.

The 2026 National Lipid Association update reinforces that FH remains severely underdiagnosed despite a global prevalence of approximately 1 in 311, emphasizing the need for systematic screening approaches 5.

References

Related Questions

What are the 2026 American Heart Association (AHA) and American College of Cardiology (ACC) lipid guideline recommendations for managing elevated triglycerides?
What is the recommended management for a 35‑year‑old patient with BMI (body mass index) 32, family history of premature cardiovascular disease, blood pressure 138/88 mmHg, total cholesterol 232 mg/dL, LDL (low‑density lipoprotein) 125 mg/dL, HDL (high‑density lipoprotein) 34 mg/dL, triglycerides 342 mg/dL, and normal creatinine (renal function) and hemoglobin A1c (glycated hemoglobin)?
How should I manage a 44-year-old male with hypercholesterolemia, hypertriglyceridemia, prediabetes (hemoglobin A1c 6.6%), elevated transaminases (aspartate aminotransferase 65 U/L, alanine aminotransferase 82 U/L), and consuming 11 alcoholic drinks per week?
What is the appropriate treatment for a 46-year-old female who is hypertensive, non-diabetic, has a family history of diabetes and coronary artery disease, LDL cholesterol of 168 mg/dL, and a 10‑year ASCVD risk of less than 5%?
What is the appropriate primary-prevention management for a patient with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 8.5%?
What symptoms would adrenal tumors present with in children?
What is the recommended protein shake regimen for safe weight loss, including appropriate calorie and protein amounts and any necessary precautions?
Which blood tests should be ordered to evaluate a patient with respiratory symptoms, fever, and abdominal discomfort?
What is the appropriate management of chronic hypertension in a 27-year-old woman at 12 weeks gestation on labetalol with a blood pressure of 159/91 mm Hg?
What is the appropriate treatment for acute frontal sinusitis with fever lasting three days?
What is the appropriate emergency management for an allergic reaction (anaphylaxis) in an adult?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.